report fiscal adjust ep
consensu expect lower estim strong revenu
lower tax rate drove upsid versu consensu lower-than-
anticip adjust oper margin account modest downsid
versu forecast
ste fiscal revenu increas year-over-year million
consensu expect million estim
million quarter compani achiev constant currenc
organ growth well forecast driven
high-single-digit low-double-digit year-over-year increas four
ste fiscal adjust oper margin declin bp year-over-year
estim quarter start-up expens
compani initi outsourc steril reprocess facil
expect begin contribut revenu fiscal slightli
larger headwind reduc fiscal gross margin bp year-over-
year versu bp declin addit adjust sg expens
higher anticip said maintain expect
roughli bp adjust oper margin expans full year
ste combin order backlog healthcar life scienc product
increas year-over-year million end fiscal
compani healthcar capit backlog strong year-
over-year million life scienc backlog declin year-
over-year reflect time issu life scienc capit sale year-
over-year fiscal difficult prior year comparison
rais guidanc constant currenc organ growth
notabl compani organ growth outlook unchang fiscal
out-performance fiscal contribut improv
organ growth guidanc addit increas adjust
ep outlook reflect higher organ
growth expect lower adjust tax rate assumpt versu
previous compani free cash flow guidanc
million also maintain increment one-tim expens associ
ste plan redomicil ireland due brexit concern offset
posit core busi trend rais adjust
ep estim
total debt total asset
encourag ste strong fiscal well favor
healthcar backlog posit enter fiscal also continu believ
sustain organ growth think could contribut
modest multipl expans current level reiter buy rate
increas price target
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect lower
estim strong revenu lower tax rate drove upsid versu consensu lower-than-
anticip adjust oper margin account modest downsid versu forecast
ste fiscal revenu increas year-over-year million consensu
expect million estim million quarter compani achiev constant
currenc organ growth well forecast driven high-single-digit low-
plcfiscal adjust incom statement revenu analysisnorthcoast research thousand except percentag per share gross sg sg oper oper interest expens incom incom tax incom extra margin extra incom com share growth ep growth life appli steril healthcar specialti compani report northcoast research estim factset double-digit year-over-year increas four divis note ste organ growth fiscal
also repres best perform seven year
growth posit fiscal forecast
quarter ste healthcar capit consum revenu increas low-double-digit rate
organ compani healthcar servic busi grew roughli exclud currenc chang
notabl ste healthcar equip organ growth strong driven primarili infect prevent
technolog capit compani healthcar equip order backlog also year-over-year
steri plcorgan growth analysi benefit signific year-over-year increas shipment hurt difficult year-over-year comparison shipmentssourc compani report northcoast research plchealthcar product organ growth analysi benefit signific year-over-year increas shipment hurt difficult year-over-year comparison shipmentssourc compani report northcoast research million end fiscal suggest favor trend continu addit easi year-
over-year comparison year-over-year fiscal fiscal think ste strong new
product launch activ healthcar equip includ earli launch v-pro max
endo also aid backlog posit total maintain expect mid-single-digit healthcar
capit organ growth seem impli conserv assumpt fiscal given strong
fiscal given comp compani backlog
fiscal ste life scienc busi post organ growth estim
compani expect sale time issu hurt fiscal result revers fiscal lead roughli
organ growth life scienc capit sale quarter contrast life scienc consum servic revenu
rel weak organ said expect improv segment futur
quarter compani begin see benefit recur revenu stream creat strong
life scienc capit sale high-teen year-over-year
ste appli steril ast busi achiev organ growth fiscal
forecast compani point increas demand core medic devic custom
primari growth driver ast quarter think capac expans favor price also
help notabl ste ast organ growth hurt next three quarter end
compani outsourc steril process agreement sterilm occur august
steri plcorder backlog analysi northcoast researchord backlog order scienc order scienc compani report northcoast research estim aid black diamond video acquisitionsteri plclife scienc divis organ growth analysi compani report northcoast research disclos compani last earn call total chang expect reduc ste revenu
million littl impact net incom
ste healthcar specialti servic busi achiev constant currenc organ growth fiscal
forecast believ market growth instrument repair track mid-single-
digit rang keep pace market legaci synergi health outsourc steril process
busi also appear perform well benefit significantli compani initi
outsourc steril process contract start fiscal includ outsourc reprocess center
northwel expect commenc oper near futur note continu expect
million fiscal outsourc steril process revenu northwel sever addit custom
annual revenu account expect ramp million time
ste fiscal adjust oper margin declin bp year-over-year
estim quarter start-up expens compani initi outsourc steril reprocess facil
plcappli steril technolog divis organ growth analysissourc compani report northcoast research plchealthcar specialti servic divis organ growth analysissourc compani report northcoast research slightli larger headwind reduc fiscal gross margin bp year-over-year versu bp
declin addit adjust sg expens higher anticip segment
standpoint strength ste healthcar product ast adjust oper margin off-set
previously-discuss margin pressur healthcar specialti servic neg mix shift lower-margin capit
sale life scienc million year-over-year increas corpor expens partial reflect higher
performance-bas compens given strength ste fiscal result rel last year
rais guidanc constant currenc organ growth notabl compani
organ growth outlook unchang fiscal out-performance fiscal contribut
improv guidanc addit increas adjust ep outlook
reflect higher organ growth expect lower adjust tax rate assumpt versu
previous compani free cash flow guidanc million also maintain
increment one-tim expens associ ste plan redomicil ireland due brexit concern
rais adjust ep estim
overal encourag ste strong fiscal well favor healthcar backlog posit enter
fiscal also continu believ sustain organ growth think could
contribut modest multipl expans current level reiter buy rate
increas price target
plcadjust oper margin healthcar life appli steril healthcar specialti fiscal exclud corpor expensesourc compani report northcoast research
steri plcannual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg oper oper net interest expens interest net expens incom incom incom tax minor net incom extra net margin extra extra net incom continu net wghd com share ep ep revenu growth adjust ep growth compani report northcoast research estim result adjust reflect adopt disclosur
